Drugs / AADvac1
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03174886 | Jul 2017 → Nov 2020 | progressive non-fluent aphasia | Axon Neuroscience SE | Unknown | No outcome recorded |
| Phase 1 | NCT02031198 | Jan 2014 → Aug 2016 | Alzheimer disease | Axon Neuroscience SE | Completed | No outcome recorded |
| Phase 1 | NCT01850238 | May 2013 → Mar 2015 | Alzheimer disease | Axon Neuroscience SE | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07167966 | Nov 2026 → Aug 2028 expected | Alzheimer disease | Paul S. Aisen | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT07173803 | Jul 2026 → Sep 2030 expected | progressive supranuclear palsy | Adam Boxer | Recruiting | No outcome recorded |
| Phase 2 | NCT06957418 | Jul 2026 → Aug 2028 expected | Alzheimer disease | Paul S. Aisen | Recruiting | No outcome recorded |
| Phase 2 | NCT07217665 | Jun 2026 → Sep 2030 expected | progressive supranuclear palsy | Adam Boxer | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02579252 | Mar 2016 → Jun 2019 | Alzheimer disease | Axon Neuroscience SE | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-25 | AlzProtect SAS | Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial announces the selection of AADvac1 and AZP2006 for its first two regimens alzprotect.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AADvac1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07173803 ↗ |
| Action | Inhibit | “These antibodies are expected to prevent tau protein from aggregating, to facilitate the removal of tau protein aggregates and prevent the spreading of pathology, slowing or...” NCT02579252 ↗ |
| Modality | Vaccine | “AADvac1 is a vaccine (single-use vials with solution ready for injection)” NCT01850238 ↗ |
| Route | Subcutaneous | “AADvac1 is administered subcutaneously” NCT01850238 ↗ |